NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Oxford BRC’s ability to deliver rapid COVID-19 research response highlighted

Oxford BRC’s ability to deliver rapid COVID-19 research response highlighted

22 February 2022 · Listed under COVID-19, Life-saving Vaccines, Translational Data Science

Oxford Biomedical Research Centre (BRC) researchers have highlighted how the BRC’s infrastructure gave it the agility and capacity to respond rapidly with research projects to tackle COVID-19.

The Oxford COVID-19 vaccine trial was able to get under way quickly thanks in part to early funding from the Oxford BRC (photo: John Cairns, University of Oxford)

In a commentary published in the open access BMC Health Research Policy and Systems journal, the BRC team said the development of the Oxford AstraZeneca (AZ) vaccine and the RECOVERY Trial, the world’s largest trial of potential treatments for COVID-19, were examples that “illustrate capability and capacity at an organizational and individual level in a dynamic environment to respond during the COVID-19 public health challenge”.

It went on: “This response was underpinned by swift adaptation and repurposing of existing research resources and expertise by the Oxford BRC to deliver rapid research to address different aspects of COVID-19. Rapid response research in turbulent environments requires strategic organizational leadership to create resilient infrastructure and resources.”

At the beginning of the pandemic, Oxford BRC research funding was quickly reallocated to ‘pump-prime’ emerging high-impact COVID-19-related research, including the Oxford/AZ vaccine and the RECOVERY trial. One year later, it had supported more than 100 COVID-19 projects, 34 of which were Urgent Public Health (UPH) research studies nationally prioritised by the NIHR.

Oxford BRC Director Prof Helen McShane said: “We’re proud that – thanks to our structure, governance and collaborative leadership – we were agile enough to reallocate funding quickly and facilitate the adaptation and repurposing of existing resources and expertise to deliver rapid research that addressed the most pressing issues relating to the pandemic., not least the development of a vaccine and identifying effective treatments.”

She added: “As a partnership between a leading NHS Foundation Trust and the world’s highest-ranked institution for medical teaching and research, the Oxford BRC was particularly well placed to deliver rapid COVID-19 research. Not only are many of its researchers also practising clinicians providing direct care to patients, alongside their academic work. Its research is fully integrated with Oxford’s hospitals, ensuring medical innovations can implemented quickly in the clinical setting.”

The Oxford BRC provided crucial early funding to accelerate the development of the COVID-19 vaccine, work led by researchers in its Vaccines Theme, and then contributed to a clinical trial to evaluate the safety of the vaccine.

The BRC was also one of the institutions that contributed to the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which has identified three effective treatments for those hospitalised with COVID-19, as well as ruling out a number of other potential treatments. This UPH trial, co-led by Professor Martin Landray, BRC Theme Lead for the Clinical Informatics and Big Data, was rolled out at record speed, with the first patient being enrolled just nine days after the protocol was first drafted.

The paper points out that the creation of the NIHR BRCs by Professor Dame Sally Davies’ in 2006 created strong research infrastructure and significant funding, which positioned the UK as a world leader in clinical research.

It highlights the foresight in creating this translational research funding and infrastructure, which led to significant expansion in the capacity and capability of translational research and the establishment of BRCs, but also its integration with the NHS, which helped to “facilitate agile response to crises”.

Oxford BRC Senior Manager Dr Lorna Henderson, lead author of the paper, said: “The researchers the BRC supports were instrumental in rapidly establishing numerous COVID-19 research studies, which went on to have truly global impact.

“This commentary highlights the importance of organisational resilience and strategic leadership underpinning the response to public health crises at speed. It forms part of a collection of papers on the role of the health research system during the COVID-19 epidemic and captures the specific contribution of BRCs in tackling the pandemic.”

← COVID-19 blog: accelerating testing with robotics
NIHR highlights QCOVID role in tackling pandemic →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre